Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 14/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16815687 | 0.82 | MAPT (0.52) | KMT2AMAPTSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL16815482 | 0.82 | CYP1A2 (0.58) | KMT2AMAPTSMN1; SMN2RAB9ACYP1A2 | |
| SCHEMBL16815681 | 0.82 | KMT2A (0.49) | KMT2AMAPTSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL20742511 | 0.78 | KMT2A (0.46) | KMT2AMAPTSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL18342623 | 0.78 | KMT2A (0.46) | KMT2AMAPTSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL20742657 | 0.77 | KMT2A (0.48) | KMT2AMAPTSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL16815697 | 0.77 | CYP1A2 (0.50) | KMT2AMAPTSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL18342624 | 0.76 | KMT2A (0.44) | KMT2AMAPTSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL16815503 | 0.75 | MAPT (0.54) | KMT2AMAPTSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL20742393 | 0.72 | SMN1; SMN2 (0.46) | KMT2AMAPTSMN1; SMN2RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2022-08-18 | — | — | US | disclosed |
| US-20210292339-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2021-09-23 | — | — | US | disclosed |
| CN-112739343-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-112533598-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3668503-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668504-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20190055264-A1 | Macrocyclic MCL-1 inhibitors and methods of use | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-02-21 | — | — | US | disclosed |
| WO-2019035899-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035914-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292339-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | KMT2A 1375/4885MAPT 4499/4885SMN1; SMN2 609/4885 |
| US-20190055264-A1 | Macrocyclic MCL-1 inhibitors and methods of use | MCL1, BCL2A1, BCL2L10 | KMT2A 1375/4885MAPT 4499/4885SMN1; SMN2 609/4885 |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | KMT2A 1375/4885MAPT 4499/4885SMN1; SMN2 609/4885 |
| US-20220259226-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | KMT2A 1375/4885MAPT 4499/4885SMN1; SMN2 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.